| Intercell Announces Q4 and Preliminary Full Year 2010 Financial Results - PR Newswire (press release) |
|
|
PR Newswire (press release) The study, conducted by Intercell's collaborator, Merck & Co., Inc., was designed to evaluate the safety and immunogenicity of the vaccine in patients with end-stage renal disease (ESRD) undergoing hemodialysis treatment. |